TNSS assessment for allergic rhinitis severity (0–12 scale)
Rate each symptom 0=None to 3=Severe. Daily assessment recommended.
sneezing:
congestion:
itch:
rhinorrhea:
TNSS Total
0/12
Controlled
Confidence
High
0
Sneezing
0
Congestion
0
Itching
0
Runny Nose
✅ Excellent control. Continue current regimen (if any). No intervention needed.
💡 Clinical Pearl
TNSS captures symptom burden snapshot. For treatment decisions, track TNSS over 3 months prior. Early seasonal rhinitis is often undertreated—patients adapt and normalize symptoms. Ask: "How does this affect your sleep, work, sports?" Poor TNSS control despite max medical therapy suggests need for immunotherapy or newer biologic (dupilumab) referral.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Standardized monitoring of allergic rhinitis (AR) severity in clinical practice and clinical trials.
Evaluating the efficacy of pharmacological interventions (e.g., antihistamines, INCS).
Patient self-monitoring during pollen seasons or after allergen exposure.
Assessing the severity of symptoms before and during subcutaneous (SCIT) or sublingual (SLIT) immunotherapy.
Section 2
Formula & Logic
Scoring Variables
Nasal Congestion / Obstruction.
Sneezing.
Nasal Itching.
Rhinorrhea (Runny Nose).
Severity Grading (for each symptom)
Score
Severity
Description
0
None
No symptoms present
1
Mild
Symptoms present but not annoying; no interference with sleep/activity
2
Moderate
Symptoms are annoying; some interference with sleep/activity
3
Severe
Symptoms are very troublesome; substantial interference
Total Score
The TNSS is the sum of the four symptom scores (range 0–12). Some versions include a 5th symptom (Ocular itching/watering) for a total of 15.
Section 3
Pearls/Pitfalls
The "Refractory" Obstruction
Nasal congestion is often the symptom least responsive to H1-antihistamines and most responsive to Intranasal Corticosteroids (INCS). A high sub-score for congestion often dictates therapy choice.
Timing of Assessment
TNSS can be "instantaneous" (symptoms right now) or "reflective" (average over the last 12 or 24 hours). Research has shown reflective scores are more stable for long-term monitoring.
Section 4
Next Steps
Management According to ARIA
01
TNSS 0–4 (Mild): Intermittent or Persistent symptoms. Use PRN oral/nasal H1-antihistamines.
While symptom diaries have existed for decades, the 4-symptom TNSS was standardized by consensus groups (e.g., ARIA) to provide a uniform primary endpoint for FDA and EMA allergic rhinitis trials.
